Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting it...
SUNRISE, Florida, USA, July 09, 2024 (GLOBE NEWSWIRE) - MedPro International, through its philanthropic Global Giving program, sponsored medical services to more than 300 patients at a one-day event i...